Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8473051 | 0.85 | PTGS2 (0.64) | PTGS1PTGS2KMT2ACA12CA1 | |
| SCHEMBL7885098 | 0.85 | PTGS2 (0.64) | PTGS1PTGS2KMT2ACA12CA1 | |
| SCHEMBL362211 | 0.85 | PTGS2 (0.64) | PTGS1PTGS2KMT2ACA12CA1 | |
| SCHEMBL2397495 | 0.85 | KMT2A (0.45) | PTGS1PTGS2KMT2ACA12CA1 | |
| SCHEMBL3954798 | 0.84 | PTGS2 (0.55) | PTGS1PTGS2KMT2ACA12CA1 | |
| SCHEMBL490403 | 0.84 | PTGS2 (0.51) | PTGS1PTGS2KMT2AAKR1C3AKR1C2 | |
| SCHEMBL11125548 | 0.84 | PTGS1 (0.46) | PTGS1PTGS2KMT2AMEN1ALDH1A1 | |
| SCHEMBL4697541 | 0.83 | FABP4 (0.48) | KMT2ACA12CA1CA2CA7 | |
| SCHEMBL28313768 | 0.83 | PTGS2 (0.47) | PTGS1PTGS2CA12CA1CA2 | |
| SCHEMBL9715766 | 0.82 | KMT2A (0.50) | PTGS1PTGS2KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6451334-B2 | PULSE ADMINISTERING OF A C1-C4 SUBSTITUTED AND/OR PHENYL SUBSTITUTED CARBOXYLIC ACID AND SALTS AND A CARRIER OR DILUENT TO STIMULATE CELLS IN TREATING BLOOD DISORDERS, E.G. SICKLE CELL ANEMIA, THALASSEMIA, BLOOD LOSS ETC. | Perrine, Susan P. | 2002-09-17 | — | — | US | claimed |
| CN-117597327-A | Pharmaceutical preparation | 第一波动生物制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-112105610-B | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-112105610-A | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| US-8268293-B2 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| CN-101163659-B | Antioxidants | MERCK PATENT GMBH | 2012-09-05 | — | — | CN | disclosed |
| US-8106233-B2 | Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing | MERCK PATENT GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-20030188344-A1 | Compositions and methods for agrobacterium transformation of plants | PENNSYLVANIA UNIVERSITY OF | 2003-10-02 | — | — | US | disclosed |
| US-6451334-B2 | PULSE ADMINISTERING OF A C1-C4 SUBSTITUTED AND/OR PHENYL SUBSTITUTED CARBOXYLIC ACID AND SALTS AND A CARRIER OR DILUENT TO STIMULATE CELLS IN TREATING BLOOD DISORDERS, E.G. SICKLE CELL ANEMIA, THALASSEMIA, BLOOD LOSS ETC. | Perrine, Susan P. | 2002-09-17 | — | — | US | disclosed |
| US-20010027215-A1 | Compositions and administration of compositions for the treatment of blood disorders | SUSAN PERRINE | 2001-10-04 | — | — | US | disclosed |
| US-6231880-B1 | ANTIGROWTH AGENTS FOR CELLS BY STIMULATING TO PATIENTS AND EFFECTIVE DIMETHYL SUBSTITUTED CARBOXYLIC ACID | Perrine, Susan P. | 2001-05-15 | — | — | US | disclosed |
| EP-0706521-A1 | NOVEL IMIDES | CELGENE CORPORATION (US) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995001348-A2 | IMIDES AS INHIBITORS OF TNP ALPHA | CELGENE CORPORATION (US) | 1995-01-12 | — | — | WO | disclosed |
| US-4769368-A | DOPAMINE ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1988-09-06 | — | — | US | disclosed |
| EP-0233049-A1 | 2,3,4,8,9,9a-Hexahydro-4-aryl-1H-indeno[1,7-cd]azepines | SMITHKLINE BECKMAN CORPORATION (US) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | PTGS1 262/4885PTGS2 320/4885KMT2A 4023/4885 |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | HPD, HAAO, UGT1A6 | PTGS1 1937/4885PTGS2 1873/4885KMT2A 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.